GlassScriptPhysician profile
Lillian E Gierhart
NPI 1649319518
$1,583.02
in general payments reported to CMS, 2019-2025
18 companies · $523 in 2025
The $523 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $330 · 2022: $265 · 2023: $350 · 2024: $115 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $240.35 | 2021-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $210.60 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Corium, LLC | $151.16 | 2025 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $148.59 | 2021-2025 | Airsupra, Farxiga |
| Axsome Therapeutics, INC. | $144.81 | 2022-2025 | Auvelity |
| Abbvie INC. | $133.14 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.62 | 2022-2023 | |
| Lilly USA, LLC | $97.90 | 2021-2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $68.75 | 2021-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.27 | 2022-2025 | Xifaxan |
| Alkermes, INC. | $43.10 | 2025 | Lybalvi |
| Lundbeck LLC | $34.78 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $28.36 | 2025 | |
| Globus Medical, INC. | $22.32 | 2025 | Senza |
| Dexcom, INC. | $18.22 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $15.58 | 2024 | (Ck7) Extended Holter |
| Pfizer INC. | $15.52 | 2025 | |
| Genentech USA, INC. | $14.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lillian Gierhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.